1-855-378-42281-855-378-4228
One of the outpatient treatment alternatives for people in Middlesboro battling with opioid dependence and addiction is opioid maintenance therapy. Licensed facilities and doctors are authorized to dispense specific medications to opioid dependent people, many that are opioid-based themselves and are addiction. In low enough doses the user does not experience being high and also doesn't experience acute cravings and is not experiencing opioid withdrawal. Methadone is the first medication used for this reason, but there are alternative options to select from.
Methadone is an opiate and can be taken at an out-patient clinic licensed to administer the med, that is taken on a daily basis as a pill or liquid. The cost of the med is about one hundred and fifty dolloars a month. Buprenorphine is also an opiate based drug, and is in pill form often taken every other day. But different from Methadone that is only be given in highly structured clinics, Buprenorphine can be prescribed and dispensed in doctor's offices. The monthly cost of buprenorphine is approximately just under $300 monthly for the generic version of the medication. There is also a version of buprenorphine containing the drug naloxone, which is a drug that reverses the effects of opioids. An individual taking this formulation, also known as Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It is also taken every day, and costs about $450 per month. Naltrexone is an additional medication taken in opioid maintenance therapy, but unlike the other drugs mentioned it is an opiate blocker and is not an opiate. There is an option to take this medication as a monthly injection, which is called Vivitrol. As an opioid blocker, the drug prevents a person from experience being high from opioids, and therefore lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 monthly.
For All Drug and Alcohol Treatment Programs In Middlesboro, Click Here.
